2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related
  5. IL-13 Isoform

IL-13

 
Cat. No. Product Name Effect Purity
  • HY-P9926
    Dupilumab
    		Inhibitor ≥99.2%
    Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
  • HY-17002
    Suplatast (Tosilate)
    		Inhibitor 98.33%
    Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis.
  • HY-P99025
    Lebrikizumab
    		Inhibitor 99%
    Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function.
  • HY-P99053
    Tralokinumab
    		Inhibitor
    Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling.
  • HY-P99496
    Cendakimab
    		Inhibitor
    Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule.
  • HY-P99238
    Rolinsatamab
    		Inhibitor
    Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody.
  • HY-P99417
    Abrezekimab
    		Inhibitor
    Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13.
  • HY-144684
    PDE4-IN-8
    		Inhibitor
    PDE4-IN-8 (Example 5) is a potent PDE4 inhibitor with an IC50 of 0.93 nM for PDE4B2.
Cat. No. Product Name / Synonyms Species Source